Sickle Cell Disease Program
Our Sickle Cell Disease Program offers comprehensive clinics, transfusion services, specialty clinics and inpatient care. In addition, we have innovative services and technology for sickle cell disease, such as transcranial Doppler (TCD) screening to evaluate patients for stroke risk and BMT for eligible candidates. We offer a transition program for our adolescent and young adult patients to make a smooth transition to an adult-care facility.
We are a member of the Sickle Cell Clinical Research Network through the NIH ASH Research Collaborative and the Atlanta Sickle Cell Consortium, a citywide collaboration of physicians and researchers advancing the treatment of sickle cell disease and trying to develop a cure. Additionally, we work with experts and treatment centers throughout the country to conduct clinical research studies with a focus on improving the quality of life and reducing complications for children affected by this disease.
We are recognized as the largest pediatric sickle cell disease program in the nation, treating over 2,000 unique patients each year. We have amassed a unique database of health outcomes data for patients followed in our Sickle Cell Disease Program. This database, comprised of roughly 4,000 unique patients, provides a rich resource for studying the health impact of sickle cell disease on children.
Our sickle cell disease team:
- David Archer, PhD
- Pauline Balkaransingh, MD, MPH
- Kenneth Busby, DO, MPH
- Toni Chanroo, MD, MPH
- Carlton Dampier, MD
- Neha Desai, DO
- Beatrice Gee, MD, Program Director
- Elaissa Hardy, PhD
- Clinton Joiner, MD, PhD
- Kirshma Khemani, MD
- Wilbur Lam, MD, PhD
- Solomon Ofori-Acquah, PhD
- Chinoso Onuoha, MD
- Ashwin Patel, MBBS, PhD, MPH
- Jason Payne, MD, Medical Director at Hughes Spalding
- Yongzhi Qiu, PhD
- Vivien Sheehan, MD, PhD
- Amy Tang, MD
- Reginald Tran, PhD
- Francesca Vinchi, PhD
- Marianne Yee, MD, MSc